China National Accord Medicines Corp Ltd
SZSE:000028
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
China National Accord Medicines Corp Ltd's latest stock split occurred on Jun 1, 2023
The company executed a 1-for-1 stock split, meaning that for every share held, investors received 1 new share.
Before the split, China National Accord Medicines Corp Ltd traded at 58.5 per share. Afterward, the share price was about 42.73.
The adjusted shares began trading on Jun 1, 2023. This was China National Accord Medicines Corp Ltd's 6th stock split, following the previous one in Sep 11, 2000.
Global
Stock Splits Monitor
China National Accord Medicines Corp Ltd
Glance View
China National Accord Medicines Corp Ltd, nestled within the bustling healthcare landscape of China, operates at the heart of the pharmaceutical distribution and retail sectors. Established with the goal of ensuring that essential medicines and healthcare services are accessible to the vast Chinese population, the company has built an extensive distribution network. This network efficiently links manufacturers with hospitals, clinics, and pharmacies, making certain that a myriad of pharmaceutical products reach their intended destinations. By leveraging a combination of logistical prowess and vast geographical coverage, the company adeptly navigates the complexities of supply chain management, underscoring its role as a critical player in China's healthcare infrastructure. Beyond distribution, China National Accord Medicines also capitalizes on the booming retail pharmaceuticals market through its chain of pharmacies. These retail outlets serve as direct points of sale to consumers, offering both prescription and over-the-counter medications, alongside health consultation services. This dual focus on both wholesale distribution and retail outlets enables the company to capture value across the supply chain, from manufacturer to end-user. The strategic alignment of its operations streamlines efficiency and generates revenue, sustaining its growth amid a fiercely competitive and rapidly evolving market. Through this integrated approach, the company solidifies its position as a crucial conduit in the delivery of healthcare solutions across China.
CUE
3902
MMI